CSL’s haemophilia therapy shows durable five-year benefits in landmark trial results

The release of positive five-year data comes at a critical moment in Australia, where the Medical Services Advisory Committee has recently issued a recommendation on HEMGENIX, and CSL has indicated it is unlikely to accept the outcome. …